XTX Topco Ltd Sells 3,426 Shares of Bioventus Inc. (NYSE:BVS)

XTX Topco Ltd decreased its position in shares of Bioventus Inc. (NYSE:BVS) by 8.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 37,734 shares of the company’s stock after selling 3,426 shares during the quarter. XTX Topco Ltd’s holdings in Bioventus were worth $451,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in BVS. Royce & Associates LP bought a new position in shares of Bioventus during the 3rd quarter worth $8,337,000. Renaissance Technologies LLC lifted its stake in shares of Bioventus by 401.5% during the 2nd quarter. Renaissance Technologies LLC now owns 503,175 shares of the company’s stock worth $2,893,000 after purchasing an additional 402,841 shares during the last quarter. Segall Bryant & Hamill LLC purchased a new stake in shares of Bioventus during the 3rd quarter worth $4,515,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Bioventus during the 3rd quarter worth $3,092,000. Finally, State Street Corp lifted its stake in shares of Bioventus by 38.8% during the 3rd quarter. State Street Corp now owns 676,501 shares of the company’s stock worth $8,084,000 after purchasing an additional 189,216 shares during the last quarter. Institutional investors own 62.94% of the company’s stock.

Bioventus Trading Down 1.0 %

Bioventus stock opened at $11.03 on Friday. The stock has a 50-day moving average of $12.08 and a two-hundred day moving average of $9.54. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. Bioventus Inc. has a one year low of $3.90 and a one year high of $14.38. The stock has a market cap of $895.14 million, a PE ratio of -18.08 and a beta of 0.79.

Bioventus (NYSE:BVS) last released its quarterly earnings results on Tuesday, November 5th. The company reported $0.06 EPS for the quarter, meeting analysts’ consensus estimates of $0.06. Bioventus had a positive return on equity of 15.61% and a negative net margin of 7.11%. The company had revenue of $138.96 million during the quarter, compared to analysts’ expectations of $132.57 million. During the same period last year, the business posted $0.05 earnings per share. On average, research analysts anticipate that Bioventus Inc. will post 0.41 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Craig Hallum upped their price objective on Bioventus from $12.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, September 27th. Canaccord Genuity Group upped their price objective on Bioventus from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.